Delivery Order SPE2DR25D2100-SPE2DR26FA1BL
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,276.80 to AmerisourceBergen Drug Corp for Risperdal 0.5 mg tablets (60-count) on October 27, 2025, with completion scheduled for October 28, 2025. This firm fixed-price delivery order represents a competitive, non-set-aside award with performance at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $2,373.84 to AmerisourceBergen Drug Corp for Risperdal 0.5 mg tablets (60-count units) with an ultimate completion date of July 29, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award supporting federal pharmaceutical procurement needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its Corporate Office location...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Risperdal 0.5 mg tablets (60 count) with a ceiling value of $3,787.60. This competitively awarded, firm fixed-price delivery order is set to be completed by August 7, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a single delivery order under AmerisourceBergen's larger pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Risperdal 0.5 mg tablets (60-count) under a firm fixed-price contract valued at $4,422.59. The order, issued on December 4, 2025, with an ultimate completion date of December 5, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for the supply of Risperdal 4 mg tablets (60-count units) with a firm fixed price ceiling value of $2,526.04. The order was competitively awarded without set-aside designation and is scheduled for completion by November 21, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for supply of Risperdal 0.5 mg tablets (60-count) under a firm fixed price contract valued at $2,391.54. This is a non-set-aside competitive award with an ultimate completion date of December 8, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,046.40 to AmerisourceBergen Drug Corp for the supply of Risperdal 0.5 mg tablets (60-count units) on September 15, 2025, with an ultimate completion date of September 16, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child order under...
- The Defense Logistics Agency awarded a $12,175.63 delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Risperdal 2 mg tablets in quantities of 60 units. This competitively awarded, firm fixed-price contract includes performance through September 11, 2025, with the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The contract carries no set-aside designation, reflecting the contractor's...
- The Defense Logistics Agency's Medical Supply Chain awarded a $2,130.74 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Risperdal 0.5 mg on September 19, 2025, with a completion date of September 22, 2025. This competitively awarded, non-set-aside contract reflects a firm fixed-price delivery order structure typical of the agency's pharmaceutical procurement operations. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $1,037.00 to AmerisourceBergen Drug Corp for the supply of Risperdal (risperidone) 0.5 mg tablets in a quantity of 60 tablets. The contract was awarded on September 24, 2025, with an ultimate completion date of September 25, 2025, utilizing firm fixed-price pricing with no set-aside designation. Performance of this delivery will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- SPE2DR25D2100Indefinite Delivery Contract
- SPE2DR25D2100-SPE2DR26FA1BLDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,361.07 to AmerisourceBergen Drug Corp for the supply of Risperdal 0.5 mg tablets (60 count) on January 8, 2026, with a completion date of January 9, 2026. This firm fixed-price, competitively awarded delivery order was issued from Conshohocken, Pennsylvania, where the vendor maintains its corporate office. The award carries no set-aside designation, indicating it was competed on a full and open basis. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, vaccines, and other critical medical commodities. The parent company, Cencora, Inc., also holds a separate IDC with DLA Troop Support Medical valued at up to $999,999,999.00 through December 31, 2031, further demonstrating the company's significant role in federal pharmaceutical procurement for military treatment facilities and veterans' healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.4k | 1/7/26 |